$286.75
0.010%
Últ. Act.: Oct 27, 12:22 PM
AbbVie (ABBV) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
AbbVie (ABBV) emitió su última guía sobre octubre 5, 2026 para Q3 2026. La compañía estimó unas ganancias por acción en el rango de $3.73 - $3.77, en comparación con una estimación de consenso de EPS de $3.85.
En comparación con la previsión anterior, AbbVie reducido redujo su previsión de BPA desde un rango anterior de $3.84 - $3.88.
AbbVie ha emitido 67 actualizaciones de orientación entre el octubre 28, 2022 y el octubre 5, 2026. During this period, the company raised its outlook 12 times and lowered it 35 times, providing investors with insight into management's evolving expectations.
| Metric | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $3.77 | $2.66 | $2.66 | $1.78 |
| Actual | $3.65 | $2.65 | $2.71 | $1.86 |
| Surprise | -3.18% | -0.38% | +1.88% | +4.49% |
| Revenue | ||||
| Estimate | $16.76B | $14.73B | $16.39B | $15.59B |
| Actual | $16.99B | $15.00B | $16.62B | $15.78B |
| Surprise | +1.37% | +1.84% | +1.37% | +1.21% |
| Metric | Q3 '26E | Q4 '26E | Q1 '27E | Q2 '27E |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Consensus | $3.77 | $3.89 | $3.37 | $4.06 |
| Revenue | ||||
| Consensus | $17.35B | $18.30B | — | — |
| Trimestre Fiscal | Fecha reportada | EPS real | EPS estimado | Sorpresa % |
|---|---|---|---|---|
| Q2 | Jul 31, 2026 | $3.65 | $3.77 | -3.18 % |
| Q1 | Apr 29, 2026 | $2.65 | $2.66 | -0.38 % |
| Q4 | Feb 4, 2026 | $2.71 | $2.66 | 1.88 % |
| Q3 | Oct 31, 2025 | $1.86 | $1.78 | 4.49 % |
| Trimestre Fiscal | Fecha reportada | Ingresos reales | Ingresos estimados | Sorpresa % |
|---|---|---|---|---|
| Q2 | Jul 31, 2026 | $16.99B | $16.76B | 1.37 % |
| Q1 | Apr 29, 2026 | $15.00B | $14.73B | 1.84 % |
| Q4 | Feb 4, 2026 | $16.62B | $16.39B | 1.37 % |
| Q3 | Oct 31, 2025 | $15.78B | $15.59B | 1.21 % |